What's New

Medical News
& Alerts

Conferences
& Meetings


Other Medical
Resources

Employment
Opportunities

Partnering
Opportunities

Search results for: lympocyticORlymphomaORnhl
95%DGNews: Patients With HBV Twice as Likely to Develop Non-Hodgkin's Lymphoma
95%DGNews: Breakthrough MabThera data now shows patients with indolent Non-Hodgkin's Lymphoma can live longer
94%DGNews: Mabthera Approved in Europe for Maintenance Therapy in Patients With Common Form of Lymphoma
94%DGNews: Researchers Help Make Diagnostic Breakthrough With Burkitt Lymphoma
94%DGNews: Consensus Regions and Novel Recurrent Amplifications Point to Genomic Regions of Interest in High-Grade Non-Hodgkin's Lymphomas: Presented at ICML
94%DGNews: Europe Issues Positive Opinion for MabThera (Rituxmab), Treatment for Indolent Non-Hodgkin's Lymphoma
94%DGNews: AACR: Acetaminophen May Increase NHL Risk in Women
94%DGNews: AACR: Sun Exposure May Protect Against Non-Hodgkin Lymphoma
94%DGNews: European Commission Approves Zevalin (Ibritumomab tiuxetan) Radioimmunotherapy
94%DGNews: EBMT: MabThera (Rituximab) With Stem Cell And Bone Marrow Transplant Improves Outcome In Non-Hodgkin's Lymphoma
94%DGNews: DG DISPATCH - TLLC: New Treatment Strategies Available For Hodgkin's Disease And Non-Hodgkin's Lymphoma
93%DGNews: Elevated Levels of Serum-Free Light Chains Linked to Increased Risk of Lymphoma in Patients With HIV: Presented at AIDS 2010
93%DGNews: Study Identifies Promising Treatment for Aggressive Lymphoma
93%DGNews: PET-CT Detects Muscular Lymphoma Better Than CT
93%DGNews: Health Canada Endorsed Important Safety Information on Rituxan (rituximab)
93%DGNews: Childhood Measles May Protect Against Hodgkin's Lymphoma: Presented at ESMO
93%DGNews: Bexxar (Tositumomab/Iodine I 131 Tositumomab) Receives Strong Support From FDA Advisory Panel
93%DGNews: ICML: Bexxar Found to be Effective against Follicular Lymphoma
93%DGNews: Canada Approves Fludara (Fludarabine) As Treatment For Non-Hodgkin's Lymphoma
93%DGNews: ASH: Onco TCS Shrinks Lymphoma Tumors By At Least 50 Percent In Non-Hodgkin's Lymphoma Relapses
92%DGNews: Rituximab in Combination Therapy for High-Grade B-Cell Lymphoma: Presented at ASH
92%DGNews: Age May Influence Long-Term Outcome of Bone-Marrow Transplants: Presented at ASH
92%DGNews: Risk of Lymphoma in Rheumatoid Arthritis Decreased by Long-term Steroid Use: Presented at EULAR
92%DGNews: Childhood Cancers Raise Risk of Second Malignancies in Adulthood: Presented at AACR
92%DGNews: New Guidelines for Assessing Lymphoma Treatment
92%DGNews: FDA Approves Velcade(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
92%DGNews: FDA Approves Two New Indications for Rituxan(R) (Rituximab) in Patients With Non-Hodgkin's Lymphoma
92%DGNews: FDA Grants Priority Review to Velcade(R) (Bortezomib) for Injection for Treatment of Relapsed Mantle Cell Lymphoma
92%DGNews: BiovaxID Yields 89% Survival in Patients with Aggressive Non-Hodgkin's
92%DGNews: PCBs, Furans May Factor in Risk of Non-Hodgkin Lymphoma
92%DGNews: Large Study Shows Link Between Statin Use and Risk of Lymphoma: Presented at ICML
92%DGNews: Limited-Stage Follicular Lymphoma Might Be Curable: Presented at ICML
92%DGNews: Association Noted Between Certain Non-Liver Cancers and Hepatitis C
92%DGNews: ASH: Bortezomib Combats Non-Hodgkin's Lymphomas
92%DGNews: FDA Grants Fast Track Status to Velcade (bortezomib) for Injection for Relapsed and Refractory Mantle Cell Lymphoma
92%DGNews: ASCO: Rituximab Plus CHOP Effective as First Line Therapy for Mantle Cell Lymphoma and as Maintenance Therapy for Indolent Lymphoma
92%DGNews: NCCN: Rituximab Use Inserted Into New Lymphoma Guidelines
92%DGNews: ASH: New Analysis Confirms Most Complete Remissions in Follicular non-Hodgkin's Lymphoma Persist for Years Following Single Treatment with Bexxar (Tositumomab and Iodine I 131 Tositumomab)
92%DGNews: FDA Approves Bexxar in Patients With Follicular Non-Hodgkin's Lymphoma
92%DGNews: ASCO: Long-Term Survival For Aggressive Non-Hodgkin's Lymphoma Patients Improved With MabThera Plus Chemotherapy
92%DGNews: ASH: Bryostatin Less Than Impressive in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma
92%DGNews: ICML: French Researchers Offer New Guidelines for Mantle Cell Lymphoma
92%DGNews: ICML: Prognostic Factors for Relapse and Transformation of Indolent Follicular Lymphoma
92%DGNews: ASH: Bexxar (Tositumomab/Iodine I 131 Tositumomab) Promising In Treatment Of Non-Hodgkin's Lymphoma
92%DGNews: PCB Exposure May Increase Lymphoma Risk
92%DGNews: Coulter Initiates Expanded Access Program For Bexxar For Non-Hodgkin's Lymphoma
92%DGNews: DG DISPATCH - TLLC: Rituximab Promising In Relapsed Non-Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation
92%DGNews: ASH: Radioactive Epratuzumab Shows Promising Results In Aggressive NHL
91%DGNews: Patients With Indolent Lymphomas Exhibit Long-Term Survival With Tositumomab After Rituximab Failure: Presented at ASH
91%DGNews: Cytarabine Plus High-Dose Methotrexate Improves Remission Rates in Primary CNS Lymphoma
Enter keywords you wish to find information about:

Search for documents that contain:
any of these words.
this exact phrase.
all of these words.

 

 

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.

All contents Copyright (c) 1998 PSL Consulting Group Inc.
all rights reserved.